Navitas Life Sciences Announces Acquisition of DataCeutics to Augment Global Clinical Data Science Services
Navitas Life Sciences Announces Acquisition of DataCeutics Inc. to Augment Global Clinical Data Science Services
Acquires DataCeutics in a $45 MM deal
PRINCETON, N.J., Feb. 13, 2019 /PRNewswire/ — Navitas Life Sciences, a TAKE Solutions Enterprise today announced that it will be acquiring Life Sciences services player, DataCeutics in North America.
The acquisition, as part of the 2021 growth strategy, spearheads the growth of Clinical business in accordance with the global Clinical market, which is expected to reach $32.9 B by 2020. The company is poised to gain from the strategic acquisition of DataCeutics, a specialty Clinical Functional Service Provider (FSP), delivering quality statistical programming, clinical reporting and clinical data management. DataCeutics strengthens Navitas Life Sciences in its high-end Data Sciences capabilities which include Clinical Data Management, Biostatistics and Statistical Programming, Medical Writing, Data Standards and Conversions as well as bolstering relationships with major pharma companies in North America. Navitas Life Sciences plans to complement DataCeutics’ capabilities with its own AI-driven clinical platform and near real-time data insights and analytics to deliver improved outcomes for clients across safety, quality, compliance, cycle time and cost. The company has core Clinical FSP capabilities and experienced resources in Oncology, Cardiology, Pulmonology, Infectious Disease and CNS.
Dr Krishnan Rajagopalan, Chief Growth Officer, Navitas Life Sciences said, “We are delighted to begin 2019 on a high note with this key acquisition. DataCeutics strengthens our capabilities in Data Sciences and FSP / BPO services and widens our therapeutic expertise in Cardiology, Oncology, Pulmonology, CNS, Infectious diseases etc. The addition of these competencies translates to business expansion in North American, European and Asian markets.”
He further added, “We are looking forward to bolstering the Clinical business further translating to a healthier pipeline in the coming quarters.“
Benefits of the acquisition
- Ability to better target the largely untapped and continuously evolving Data Sciences field supporting R&D efforts of novel therapies across various indications
- Enhances therapeutic expertise in Cardiology, Oncology, Pulmonology, Mental health, Musculoskeletal diseases, CNS, and Infectious diseases
- An increase of Life Sciences expertise by 10%
- Combined footprint will further cover North America, Europe, and Asia
About Navitas Life Sciences
Navitas Life Sciences delivers platform-driven full-service Clinical, Regulatory and Safety solutions and services. As the dedicated life sciences brand of TAKE Solutions, Navitas Life Sciences operates across North America, Europe, Asia Pacific and Latin America. Navitas Life Sciences combines the knowledge and experience of three legacy brands – Ecron Acunova, Navitas, and Intelent. Thus, Navitas Life Sciences brings together the capabilities of a full-service CRO, a technology-led life sciences services provider, and expertise in analytics and data sciences to address critical challenges and drive outcomes for life sciences. Navitas has over 30 years of rich experience across 330+ phase I-IV clinical trials, 20+ therapeutic areas, and 40+ successful GCP/non-GCP audits. Our trial expertise is augmented by OneClinical, a platform that delivers trial oversight, analytics, and insights to drive successful study outcomes.
For more information, please visit: www.navitaslifesciences.com
Media contact:
Patrick Mullen
[email protected]
609-454-7753
SOURCE Navitas Life Sciences
Related Links
http://www.navitaslifesciences.com
PR Newswire source:
